Operates as a pharmaceutical company headquartered in Matunga, Mumbai, listed on the BSE SME Exchange. FY26 revenue was Rs 116.27 crore against total assets of Rs 94.21 crore. The cost structure shows zero materials cost, 2.6% employee costs and 13.6% other operating expenses, indicating the business is positioned around pharmaceutical trading, marketing or distribution rather than in-house drug manufacturing. The company is expanding overseas — it opened a representative branch office in Sharjah Media City Free Zone, UAE, commencing 31 March 2026, aimed at export opportunities and relationships with international clients. In FY26, short-term borrowings were reduced to Rs 1,393.92 lakhs and operating cash flow turned positive to Rs 923.57 lakhs from a negative figure the year before. Trade receivables at FY26 year-end stood at Rs 5,461.70 lakhs, indicating extended credit cycles to customers. The company is led by Managing Director Hemant C Bhagat and is exempt from detailed SEBI corporate governance norms under Regulation 15 because of its SME listing. AR · MarketPing reader · 2026-08-02
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 94 | 120 | 221 | 87 | 116 |
| EBITDA (ex other income) | — | — | — | — | — |
| margin % | — | — | — | — | — |
| Owners' profit | — | — | — | — | — |
| EPS, as reported (₹) | 1.06 | 1.20 | 2.03 | 1.14 | 4.04 |
| ROE % · ROCE % | — · 12.1 | — · 10.0 | — · 11.9 | — · 9.6 | — · 17.1 |
| Debt / equity (x) | — | — | — | — | — |
| Cash from operations | 12 | 5 | 6 | (6) | 9 |
| Capex | — | — | — | (1) | (1) |
| ₹ crore | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 44 | 75 | 119 | 102 | 65 | 22 | 26 | 91 |
| Profit before tax | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 4 |
| Net profit | — | — | — | — | — | — | — | — |
| EPS (₹) | 0.49 | 0.71 | 0.84 | 1.19 | 0.91 | 0.23 | 0.30 | 3.44 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 3 Sept 2026 · AGM results: all 4 resolutions passed; 66L convertible warrants approved | board shareholder meetings | low | — | — |
| 1 Sept 2026 · 23rd AGM held; warrants issue and capital hike among key resolutions | board shareholder meetings | low | — | — |
| 20 Aug 2026 · Corrigendum to AGM notice — adds warrant certificate link | board shareholder meetings | low | — | — |
| 6 Aug 2026 · AGM notice: capital hike to Rs 15 Cr, 66 lakh warrants at Rs 44 to promoters and others | board shareholder meetings | low | — | — |
| 6 Aug 2026 · 23rd AGM notice, FY26 annual report and warrant issue proposal | board shareholder meetings | medium | — | — |
| 5 Aug 2026 · Board approves capital hike and 66 lakh convertible warrants | corporate actions | medium | — | — |
| 30 Jul 2026 · Board meeting on 5 Aug to consider fund raising via preferential allotment | corporate actions | medium | — | — |
| 21 Jul 2026 · SME Listing Exemption From Corporate Governance Report Filing for Q1 FY26 | compliance | minimal | — | — |
| 25 May 2026 · Financial Result for the period ended 31st march 2026. | results | high | — | — |
| 25 May 2026 · Outcome of Board Meeting held on 25th May 2026 for approval of audited result for year ended 31 march 2026. | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 9.2 | 28.9 | 24 of 169 | 86% |
| ROCE | 11.5 | 10.8 | 86 of 183 | 53% |
| Revenue growth | (11.2) | 16.3 | 135 of 161 | 16% |
| Market cap | 34 | 839 | 159 of 182 | 13% |
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
